Phase 2 N=1,270 COVID-19 Variant Immunologic Landscape Trial (COVAIL Trial)
COVID-19
Primary: Geometric Mean Fold Rise (GMFR) of AUC From Baseline Antibody Against Wa-1 in One Dose Groups. — 4.57; 3.61; 3.78; 3.87 fold rise
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=32 Antibiotic Instillation in Appendicitis
Complicated Appendicitis · Acute Appendicitis
Primary: Feasibility of the Use of Antibiotic Solution Instillation Following Intraoperative Diagnosis of Complex Appendicitis as Assessed by Percentage of Eligible Participants…
Phase 2 N=82 Quantitative Mapping of Substantia Nigra Iron in Parkinson's Disease (Stages I-IV, REM Sleep Behavior Disorder) and Controls
Parkinson Disease · REM Sleep Behavior Disorder · Healthy
Primary: Change in Sensitivity of QSM MR Imaging From Baseline MR Imaging to 24 Month MR Imaging — 379.5896; 314.1832; 561.1894; 288.1832 ppb — p=0.66
Phase 2 N=20 A Comparison of NETSPOT Imaging Versus F-FDG-PET in Head and Neck Cancer Patients
Head and Neck Squamous Cell Carcinoma
Primary: Detection and Staging of Head and Neck Squamous Cell Carcinoma Using Standard Uptake Value for NETSPOT Imaging — 7.21; 4.84; 2.87; 2.46 (SUV) volume (cm3)
Phase 2 N=181 Obinutuzumab in cGVHD After Allogeneic Peripheral Blood Stem Cell Transplantation
Graft vs. Host Disease
Primary: Corticosteroid-Requiring Chronic Graft-Versus-Host Disease (cGVHD) Rate — 13.3; 35.2 percentage of participants — p=0.0008
Phase 2 N=8 Ultrasonic Deep Brain Stimulation During Anesthetic Sedation
Mental Function
Primary: Blood Oxygen Level Dependent (BOLD) Response to Visual Stimuli — 0.56; 0.51 percentage of BOLD signal — p=0.62
Phase 2 N=241 Normal Saline Infusion for Stroke After Intravenous Thrombolysis
Brain Infarct
Primary: Number of Participants With 90-day Favorable Outcome — 106; 93 Participants
Phase 2 N=191 A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Participants With Myelofibrosis
Myelofibrosis (MF)
Primary: Percentage of Participants With ≥ 35% Reduction From Baseline in Spleen Volume at Week 24 — 26.47; 21.98; 11.76; 62.50 percentage of participants
Phase 2 N=32 Ixazomib Rollover Study
Multiple Myeloma · Lymphoma · Amyloidosis
Primary: Number of Participants With Serious Adverse Events (SAEs) — 12; 4 Participants
Phase 2 N=53 Pertussis Challenge Study in Adults Vaccinated With BPZE1
Pertussis/Whooping Cough · Bordetella Pertussis, Whooping Cough
Primary: Number of Participants Colonized Following Virulent Challenge — 8; 12 Participants
Phase 2 N=162 DUET Study: A Clinical Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Orally Administered TERN-501 as Monotherapy and in Combination With TERN-101 in Noncirrhotic Adults With Presumed Non-Alcoholic Steatohepatitis
NASH - Nonalcoholic Steatohepatitis
Primary: Relative Change From Baseline in MRI-PDFF at Week 12 for TERN-501 Monotherapy (Arms 1, 2 and 3) Compared to Placebo. — -15.39; -27.48; -44.81; -4.01 Percent change from…
Phase 2 N=10 A Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of Subjects With Plaque Psoriasis
Plaque Psoriasis
Primary: Change From Baseline in the Psoriasis Area and Severity Index (PASI) — -4.3; -7.6; -8.0 score on a scale
Phase 2 N=55 IL-1 Signal Inhibition in Alcoholic Hepatitis
Alcoholic Hepatitis
Primary: Number of Patients Presenting Histological Improvement of Alcoholic Hepatitis on Liver Biopsy After 28 Days of Treatment Compared to Baseline. — 14; 10 Participants…
Phase 2 N=105 Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC)
Non-small Cell Lung Cancer
Primary: Progression Free Survival (PFS) at 18-month — 65.5; 66.3 Percentage of participants
Phase 2 N=267 A Study of Tazemetostat in Adult Participants With Soft Tissue Sarcoma
Malignant Rhabdoid Tumors (MRT) · Rhabdoid Tumors of the Kidney (RTK) · Atypical Teratoid Rhabdoid Tumors (ATRT)
Primary: Cohorts 1, 3, 4, 5, 6 and 7: Objective Response Rate (ORR) — 9.4; 9.4; 0.0; 16.1 Percentage of participants